Formerly dba (from 1973) as Btillups-Rotheaberg Inc, (BRI)had pioneered development of low-cost tissue culture incubators. Almost a half century later later, those now running the firm - renamed as Embrient Inc in 2021 - have engaged these proven designs to become the de facto standard for hypoxic experiments. Provide a full range of O2/CO2 conditions for tissue culture incubators and enable various in vitro environments, these tools are mainstays in fields such as stem cell, IVF, and malaria research in thousands of laboratories worldwide. The newly created company - Embrient Inc - has maintained/retianed the entire BRI product line and management team were retained continuing to sell BRI products and to provide funding for future, innovative new products.
